Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Coronavirus

The CATALYST Trial tested the rheumatoid arthritis treatment namilumab as a potential therapeutic to treat patients who are hospitalised with COVID-19 pneumonia and receiving 'usual' care, but who also have high levels in their blood of a protein called CRP, whose levels rise when there is inflammation in the body. Higher levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19.

Namilumab, produced by the UK-based bio-pharmaceutical company Izana Bioscience's, is an antibody that targets a 'cytokine' which is naturally secreted by immune cells in the body but, at uncontrolled levels, is believed to be a key driver of the excessive and dangerous lung inflammation seen in COVID-19 patients.

The CATALYST Trial is a collaboration between the Universities of Birmingham and Oxford and is supported by the NIHR Oxford Biomedical Research Centre (BRC). The Oxford arm of the study is led by Professor Duncan Richards of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, and Dr Matt Rowland of the Nuffield Department of Clinical Neurosciences.

Read the full story on the Nuffield Department of Clinical Neurosciences website. 

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.